The minimally important difference for the Xerostomia Inventory among Sjögren's disease patients
Oral Diseases · 2024-10 · 30 (7) · 4356-4363
DOI: 10.1111/odi.14841 ↗At a glance
Journal article in Oral Diseases, published online on 2023-12-26. Written by Zainab Assy and 8 co-authors. Institution: Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherl…. Major MEDLINE topics: Xerostomia, Sjogren's Syndrome. Cited 4 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIAID NIH HHS, National Institutes of Health.
Abstract (original language)
Objective
Until now, the clinically relevant improvement for the Xerostomia Inventory (XI) has not been defined. Therefore, our aim was to determine the Minimally Important Difference (MID) of the XI for improvement in dry‐mouth symptoms in SjD patients.
Method
The study recruited 34 SjD patients who underwent sialendoscopy of major salivary glands and 15 SjD patients in a nonintervention control group. XI scores were assessed at several time points. The MID was determined from the mean difference in XI scores between the groups with and without improvement.
Results
In the control group, no significant XI score changes were seen. In the sialendoscopy group, a clinically relevant XI score change of four scale points was identified after 1 week. For a prolonged duration (≥16 weeks), a minimum reduction of seven scale points in the XI score was required to indicate clinically relevant improvement.
Conclusion
In SjD patients, a minimum change of four points in the XI score indicates a clinically relevant improvement for evaluating short‐term effects. For prolonged effects, a clinically relevant improvement requires a MID of seven points. The determination of the MID in XI could assist in future studies that evaluate changes in xerostomia.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Amsterdam, The Netherlands.
- Sir John Walsh Research Institute, University of Otago Faculty of Dentistry, Dunedin, New Zealand.
- Department of Oral and Maxillofacial Diagnostic Sciences, Center for Orphaned Autoimmune Disorders, University of Florida, Gainesville, Florida, USA.
- Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Biochemistry, Christopher S. Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA.
- Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
ORCID profiles: Zainab Assy, William Murray Thomson, Merve M Susam, Gary A Weisman, Arjan Vissink, Floris J Bikker, Derk Hendrik Jan Jager
Funding
- NIAID NIH HHS
- National Institutes of Health
Cite
APA
Assy, Z., Thomson, W. M., Brand, H. S., Cha, S., Susam, M. M., Weisman, G. A., Vissink, A., Bikker, F. J., & Jager, D. H. J. (2024). The minimally important difference for the Xerostomia Inventory among Sjögren's disease patients. Oral Diseases, 30(7), 4356-4363. https://doi.org/10.1111/odi.14841
Vancouver
Assy Z, Thomson WM, Brand HS, Cha S, Susam MM, Weisman GA, et al. The minimally important difference for the Xerostomia Inventory among Sjögren's disease patients. Oral Diseases. 2024;30(7):4356-4363. doi:10.1111/odi.14841
BibTeX
@article{Assy2024,
author = {Assy, Zainab and Thomson, William Murray and Brand, Henk S and Cha, Seunghee and Susam, Merve M and Weisman, Gary A and Vissink, Arjan and Bikker, Floris J and Jager, Derk Hendrik Jan},
title = {The minimally important difference for the Xerostomia Inventory among Sjögren's disease patients},
journal = {Oral Diseases},
year = {2024},
volume = {30},
number = {7},
pages = {4356--4363},
doi = {10.1111/odi.14841}
}
EUVIMED